


ISSUE DATE December 11, 2023	EFFECTIVE DATE December 11, 2023	NUMBER 01-23-27, 05-23-09, 08-23-30, 09-23-26, 10-23-13, 24-23-22, 26-23-07, 30-23-18, 31-23-28, 33-23-24
SUBJECT MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines	BY  Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs	

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers about updates to the MA Program Fee Schedule related to the Current Procedural Terminology (CPT) codes for the administration of novel coronavirus (SARS-CoV-2) vaccines.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, physician assistants, pharmacists not employed by or under contract with a pharmacy, outpatient hospital-based clinics, independent medical/surgical clinics, federally qualified health centers (FQHC), rural health clinics (RHC), home health agencies, ambulance providers, renal dialysis centers, psychiatric outpatient clinics, drug and alcohol outpatient clinics, and licensed pharmacies enrolled in the MA Program who may administer SARS-CoV-2 vaccines to MA beneficiaries in the Fee-for-Service (FFS) or managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any billing questions.

BACKGROUND/DISCUSSION:

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>

On April 18, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) for the Pfizer, Inc. and Moderna, Inc. SARS-CoV-2 vaccines to allow for additional bivalent doses of the vaccines. The American Medical Association (AMA) established new CPT codes 0121A, 0151A, 0171A, 0172A (Pfizer, Inc.) as well as 0141A and 0142A (Moderna, Inc.) for the administration of bivalent doses of the SARS-CoV-2 vaccines manufactured by Pfizer, Inc. and Moderna, Inc. The codes are distinct to these bivalent doses of the Pfizer, Inc. and Moderna, Inc. SARS-CoV-2 vaccines. In response, the Department added CPT codes 0121A, 0151A, 0171A, 0172A, 0141A, and 0142A to the MA Program Fee Schedule, effective for dates of service on and after April 18, 2023, as indicated in the Procedure section below.

Additionally, on April 18, 2023, the FDA announced that the monovalent SARS-CoV-2 vaccines manufactured by Pfizer, Inc. and Moderna, Inc. are no longer authorized for use in the United States. In response, the Department end-dated these CPT codes from the MA Program Fee Schedule, effective April 17, 2023.

On May 22, 2023, Janssen Biotech, Inc. requested the voluntary withdrawal of the EUA for their SARS-CoV-2 vaccine. Janssen Biotech, Inc. informed the FDA that the last lots of the vaccine purchased by the U.S. Government have expired, there is no demand for new lots of the vaccine in the U.S., and they do not intend to update the strain composition of this vaccine address emerging variants. As a result, the FDA revoked the EUA for the SARS-CoV-2 vaccine manufactured by Janssen Biotech, Inc., effective June 1, 2023. In response, the Department end-dated these CPT codes 0031A and 0034A from the MA Program Fee Schedule, effective June 1, 2023.

On September 11, 2023, the FDA removed authorization for the use of bivalent SARS-CoV-2 vaccines manufactured by Pfizer, Inc. and Moderna, Inc. in the United States. These CPT codes had been added to the MA Program Fee Schedule for dates of service on and after April 18, 2023, as indicated below. The Centers for Medicare & Medicaid Services (CMS) end-dated these CPT codes, effective September 12, 2023. In response, the Department end-dated these CPT codes from the MA Program Fee Schedule, effective September 12, 2023, as indicated in the Procedure section below.

Finally, on September 11, 2023, the FDA amended the EUA for the Pfizer, Inc. and Moderna, Inc. SARS-CoV-2 vaccines to include the 2023-2024 Formula. The AMA established three new CPT codes for Pfizer, Inc. – 91318, 91319, and 91320 – and two new CPT codes for Moderna, Inc. – 91321 and 91322. In response, the Department added CPT codes 91318, 91319, and 91320 (Pfizer, Inc.), and 91321 and 91322 (Moderna, Inc.) to the MA Program Fee Schedule, which may be used for dates of service on and after September 11, 2023, as indicated in the Procedure section below.

On October 3, 2023, the FDA amended the EUA for the Novavax SARS-CoV-2 vaccine to include the 2023-2024 formula. CMS end-dated CPT codes 0041A, 0042A, and 0044A for the Novavax vaccine, effective October 3, 2023. In response, the Department end-dated these procedure codes from the MA Program Fee Schedule, effective October 3, 2023. The Department also added CPT code 91304 to the MA Program Fee Schedule for the

administration of the 2023-2024 Novavax SARS-CoV-2 vaccine, effective for dates of service on and after October 3, 2023, as indicated in the Procedure section below.

These CPT codes are to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered. This level of specificity offers the ability to track each vaccine, even when the vaccine product is not reported, such as when the vaccine is available at no cost.

PROCEDURE:

MA providers in both the FFS and managed care delivery systems are to bill for the administration of the bivalent doses of the SARS-CoV-2 vaccines manufactured by Pfizer, Inc. and Moderna Inc. to MA beneficiaries using the CPT codes below for dates of service between April 18, 2023, and September 12, 2023.

Vaccine Manufacturer	Code	Code Description	MA Fee
Pfizer, Inc.	0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	\$40.00
	0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	\$40.00
	0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	\$40.00
	0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	\$40.00
Moderna, Inc.	0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	\$40.00

	0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	\$40.00
--	-------	---	---------

Effective for dates of service on and after September 11, 2023, MA providers in both the FFS and managed care delivery systems are to bill for the administration of SARS-CoV-2 (2023-2024 Formula) vaccines manufactured by Pfizer, Inc. and Moderna Inc. to MA beneficiaries using the CPT codes below.

Vaccine Manufacturer	Code	Code Description	Rate
Pfizer, Inc.	91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	\$40.00
	91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	\$40.00
	91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	\$40.00
Moderna, Inc.	91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	\$40.00
	91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	\$40.00

Effective for dates of service on and after October 3, 2023, MA providers in both the FFS and managed care delivery systems are to bill for the administration of SARS-CoV-2 (2023-2024 Formula) vaccines manufactured by Novavax to MA beneficiaries using the CPT code below.

Vaccine Manufacturer	Code	Code Description	Rate
Novavax	91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use	\$40.00

NOTE: Provider type 10, specialty 100 (physician assistant) is included because physician assistants can be listed as the rendering provider pursuant to MA Bulletin 01-22-05, 08-22-05, 09-22-04, 10-22-01, 31-22-05, entitled “Billing Procedure Update for Certified Registered Nurse Practitioners and Physician Assistants.”

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2022010701.pdf>.

The Department end-dated the following CPT codes from the MA Program Fee Schedule, effective April 17, 2023, as the FDA no longer authorizes the use of monovalent SARS-CoV-2 vaccines in the United States.

End-Dated CPT Codes				
0001A	0002A	0003A	0004A	0011A
0012A	0013A	0021A	0022A	0051A
0052A	0053A	0054A	0064A	0071A
0072A	0073A	0074A	0081A	0082A
0083A	0091A	0092A	0093A	0094A
0111A	0112A	0113A		

The Department end-dated the following CPT codes from the MA Program Fee Schedule, effective June 1, 2023, as the FDA revoked the EUA for the SARS-CoV-2 vaccine manufactured by Janssen Biotech, Inc.

End-Dated CPT Codes	
0031A	0034A

The Department end-dated the following CPT codes from the MA Program Fee Schedule, effective September 12, 2023, as the FDA no longer authorizes the use of the bivalent SARS-CoV-2 vaccines identified below in the United States.

End-Dated CPT Codes				
0121A	0124A	0134A	0141A	0142A
0144A	0151A	0154A	0164A	0171A
0172A	0173A	0174A		

The Department end-dated the following CPT codes from the MA Program Fee Schedule, effective October 3, 2023, to align with CMS.

End-Dated CPT Codes		
0041A	0042A	0044A

Attached is Attachment 1 titled “MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc. and Moderna, Inc., Effective April 18, 2023, through September 12, 2023.” The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, effective date, pricing and/or informational modifiers if applicable, and MA fee for the procedure code for providers submitting MA FFS claims.

Attachment 2 titled “MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna, Inc., Effective September 11, 2023”, identifies the procedure code, national code description, provider type, provider specialty, place of service, effective date, pricing and/or informational modifiers if applicable, and MA fee for the procedure code for providers submitting MA FFS claims.

Attachment 3 titled “MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Novavax, Effective October 3, 2023”, identifies the procedure code, national code description, provider type, provider specialty, place of service, effective date, pricing and/or informational modifiers if applicable, an MA fee for the procedure code for providers submitting MA FFS claims.

FQHCs and RHCs are to bill with the applicable CPT code, as set forth above when a SARS-CoV-2 vaccine is administered to a MA beneficiary, and no other services that constitute an encounter are rendered on that date. When the SARS-CoV-2 vaccine is administered during a visit that is a billable encounter, FQHCs and RHCs are to bill procedure code T1015 to be paid their provider-specific Prospective Payment System rate and include the appropriate SARS-CoV-2 vaccine CPT code on a separate claim line for tracking purposes, with no additional payment made for the administration of the vaccine. FQHCs and RHCs may not bill the Department for, or include on their cost report, SARS-CoV-2 vaccines they receive at no cost. FQHCs and RHCs may also not bill for the administration of the vaccine for which they will be paid by another entity to administer.

MA providers who administer a SARS-CoV-2 vaccine to an MA beneficiary who is homebound should bill procedure code M0201 along with the applicable SARS-CoV-2 dose administration code. For additional information related to billing for the administration of SARS-CoV-2 vaccines to an MA beneficiary who is homebound, providers should refer to MA Bulletin 01-21-04, “SARS-CoV-2 Vaccine Administration for Beneficiaries who are Homebound” for billing instructions. The bulletin may be accessed at the link below: <https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/>

[MAB2021072901.pdf](#). For additional information related to FQHCs and RHCs billing for the administration of SARS-CoV-2 vaccines to an MA beneficiary who is homebound, providers should refer to MA Bulletin 08-20-68, "Federally Qualified Health Center and Rural Health Clinic Payment for SARS-CoV-2 Vaccine Administration" for billing instructions. The bulletin may be accessed at the link below:

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2022061001.pdf>.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx>.

Providers who may administer SARS-CoV-2 vaccines may bill for the administration of SARS-CoV-2 vaccines to MA beneficiaries experiencing homelessness when delivered in their lived environment with POS 15 and the U2 modifier for procedure codes 91318, 91319, 91320, 91321, and 91322 for dates of service between September 12, 2023, through September 30, 2023. For dates of services on and after October 1, 2023, providers may bill for the administration of SARS-CoV-2 vaccines to MA beneficiaries experiencing homelessness when delivered in their lived environment for these procedure codes with POS 27.

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the Department's Pharmacy Services Covered Drugs Search Tool on the Department's website at:

<https://www.humanservices.state.pa.us/CoveredDrugs/CoveredDrugs/Index>.

Providers may not bill the MA Program for a SARS-CoV-2 vaccine they receive at no cost or for the administration of a SARS-CoV-2 vaccine for which they will be paid by another entity to administer.

For information on how licensed pharmacies enrolled in the MA Program who provide services to MA beneficiaries should bill for the administration of SARS-CoV-2 vaccines by a pharmacist, please refer to MA Bulletin 01-20-60, "SARS-CoV-2 Vaccine Administration by Pharmacists", issued December 30, 2020, at the link below:

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2020123001.pdf>.

Additional information and guidance pertaining to the SARS-CoV-2 vaccines can be found at the following links:

- American Medical Association - <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.
- Centers for Disease Control and Prevention <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html>.

- Centers for Medicare & Medicaid Services
<https://www.medicare.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html>.
- PA Department of Health
<https://www.health.pa.gov/Pages/default.aspx>.

ATTACHMENT:

Attachment 1:

MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc. and Moderna, Inc., Effective April 18, 2023, through September 12, 2023

Attachment 2:

MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna, Inc., Effective September 11, 2023

Attachment 3:

MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Novavax, Effective October 3, 2023

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	01	183	12, 22			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	05	050, 051	12, 99			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	08	082	12, 49			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	08	110	49			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	08	184	12, 57			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	24	240, 247	12			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	26	260, 261	12, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	30	300	12, 65			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	33	335	11, 12, 99			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	01	183	12, 22			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	05	050, 051	12, 99			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	08	082	12, 49			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	08	110	49			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	08	184	12, 57			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	24	240, 247	12			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	26	260, 261	12, 99			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	30	300	12, 65			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	33	335	11, 12, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	01	183	12, 22			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	05	050, 051	12, 99			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	08	082	12, 49			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	08	110	49			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	08	184	12, 57			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	24	240, 247	12			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	26	260, 261	12, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	30	300	12, 65			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose	33	335	11, 12, 99			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	01	183	12, 22			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	05	050, 051	12, 99			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	08	082	12, 49			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	08	110	49			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	08	184	12, 57			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	24	240, 247	12			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	26	260, 261	12, 99			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	30	300	12, 65			\$40.00	No	once per day
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	33	335	11, 12, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	01	183	12, 22			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	05	050, 051	12, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	08	082	12, 49			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	08	110	49			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	08	184	12, 57			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	24	240, 247	12			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	26	260, 261	12, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	30	300	12, 65			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	33	335	11, 12, 99			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	01	183	12, 22			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	05	050, 051	12, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	08	082	12, 49			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	08	110	49			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	08	184	12, 57			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	24	240, 247	12			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	26	260, 261	12, 99			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	30	300	12, 65			\$40.00	No	once per day
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of Bivalent Doses of the SARS-CoV-2 Vaccines,
Effective April 18, 2023 to September 12, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	33	335	11, 12, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	01	183	12, 22			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	05	050, 051	12, 99			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	082	12, 49			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	110	49			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	184	12, 57			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	10	247	11			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	24	All	11, 31, 32, 99			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	24	240, 247	12			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	26	260, 261	12, 99			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	30	300	12, 65			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91318	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	33	335	11, 12, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	01	183	12, 22			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	05	050, 051	12, 99			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	082	12, 49			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	110	49			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	184	12, 57			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	10	247	11			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	24	All	11, 31, 32, 99			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	24	240, 247	12			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	26	260, 261	12, 99			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	30	300	12, 65			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91319	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	33	335	11, 12, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	01	183	12, 22			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	05	050, 051	12, 99			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	082	12, 49			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	110	49			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	08	184	12, 57			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	10	247	11			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	24	All	11, 31, 32, 99			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	24	240, 247	12			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	26	260, 261	12, 99			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	30	300	12, 65			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91320	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	33	335	11, 12, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	01	183	12, 22			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	05	050, 051	12, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	08	082	12, 49			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	08	110	49			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	08	184	12, 57			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	10	247	11			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	24	All	11, 31, 32, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	24	240, 247	12			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	26	260, 261	12, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	30	300	12, 65			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91321	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	33	335	11, 12, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	01	183	12, 22			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	05	050, 051	12, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	08	082	12, 49			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	08	110	49			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	08	184	12, 57			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	10	247	11			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc. and Moderna Inc.,
Effective September 11, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	24	All	11, 31, 32, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	24	240, 247	12			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	26	260, 261	12, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	30	300	12, 65			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91322	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	33	335	11, 12, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccine Manufactured by Novavax,
Effective October 3, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	01	183	12, 22			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	05	050, 051	12, 99			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	08	082	12, 49			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	08	110	49			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	08	184	12, 57			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day

**MA Program Fee Schedule Updates for the Administration of SARS-CoV-2 Vaccine Manufactured by Novavax,
Effective October 3, 2023**

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	10	247	11			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	24	All	11, 31, 32, 99			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	24	240, 247	12			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	26	260, 261	12, 99			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	30	300	12, 65			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use	33	335	11, 12, 99			\$40.00	No	once per day